Natixis Advisors LLC Boosts Stake in Insmed Incorporated (NASDAQ:INSM)

Natixis Advisors LLC lifted its position in Insmed Incorporated (NASDAQ:INSM) by 2.1% in the 4th quarter, Holdings Channel reports. The fund owned 21,325 shares of the biopharmaceutical company’s stock after acquiring an additional 431 shares during the quarter. Natixis Advisors LLC’s holdings in Insmed were worth $1,472,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Catalyst Funds Management Pty Ltd grew its position in shares of Insmed by 60.7% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 11,250 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 4,250 shares during the period. Picton Mahoney Asset Management boosted its stake in Insmed by 7.4% during the fourth quarter. Picton Mahoney Asset Management now owns 48,897 shares of the biopharmaceutical company’s stock worth $3,374,000 after acquiring an additional 3,354 shares in the last quarter. Swiss National Bank grew its holdings in Insmed by 6.1% in the fourth quarter. Swiss National Bank now owns 321,100 shares of the biopharmaceutical company’s stock worth $22,169,000 after purchasing an additional 18,600 shares during the period. Avantax Advisory Services Inc. increased its stake in shares of Insmed by 19.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $619,000 after purchasing an additional 1,486 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Insmed by 18.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,476 shares of the biopharmaceutical company’s stock worth $3,002,000 after buying an additional 6,755 shares during the last quarter.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the transaction, the insider now owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Down 0.7 %

INSM opened at $79.38 on Tuesday. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The firm’s 50 day simple moving average is $77.64 and its two-hundred day simple moving average is $73.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $14.37 billion, a PE ratio of -14.20 and a beta of 1.28.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Wells Fargo & Company boosted their target price on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. Stifel Nicolaus decreased their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Finally, Truist Financial increased their price target on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.